About ArsenalBio
ArsenalBio focuses on developing programmable cell therapies to treat solid tumor cancers. Their approach involves reprogramming cells to enhance their ability to fight cancer. The company is currently in the clinical stage, concentrating on research and development to bring these therapies to market. Their target audience includes patients with solid tumor cancers, a significant segment of cancer patients worldwide. ArsenalBio aims to generate revenue through the commercialization of their therapies once they receive approval. The team consists of experts from various scientific fields and professionals with clinical and manufacturing backgrounds, all working together to create effective cancer treatments.
San Francisco, CaliforniaHeadquarters
2019Year Founded
$612.8MTotal Funding
SERIES_CCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees
Benefits
Medical, dental, & vision coverage
Virtual & telehealth options
Parental leave
Flexible work schedule
Flexible PTO
Mental health resources
Risks
Emerging competition from companies like Allogene Therapeutics in CAR T-cell therapies.
High manufacturing costs may affect ArsenalBio's pricing and market competitiveness.
Regulatory scrutiny on gene-editing technologies could delay therapy approvals.
Differentiation
ArsenalBio integrates CRISPR, synthetic biology, and machine learning for advanced cell therapies.
Their focus on solid tumors sets them apart in the CAR T-cell therapy space.
ArsenalBio's CITE technology enhances T-cell targeting and tumor microenvironment overcoming.
Upsides
Recent $325 million funding boosts ArsenalBio's clinical development capabilities.
Partnerships with Thermo Fisher enhance ArsenalBio's manufacturing and technological capabilities.
Growing demand for personalized medicine aligns with ArsenalBio's programmable cell therapy focus.
Funding
Total raised$612.82 M
Latest valuation$1.63 B
StageSERIES_C
SERIES B
8/31/2022$220
$1.10 B